Expression, purification, and characterization of TYK-2 kinase domain, a member of the Janus kinase family

Biochemical and Biophysical Research Communications

Volumn 396, Issue 2, 2010, Pages 543-548

  Korniski, Brian ^a   Wittwer, Arthur J ^a   Emmons, Thomas L ^a   Hall, Troii ^a   Brown, Stacy ^a   Wrightstone, Ann D ^a   Hirsch, Jeffrey L ^a   Gormley, Jennifer A ^a   Weinberg, Robin A ^a   Leone, Joseph W ^a   Day, Jacqueline E ^a   Chrencik, Jill E ^a   Sommers, Cynthia D ^a   Fischer, H David ^a   Tomasselli, Alfredo G ^a  

^a PFIZER INC   (United States)

Author keywords

JAK 2; JAK 3; Kinase inhibitors; Kinetic; Phosphorylation; Purification; TYK 2

Indexed keywords

JANUS KINASE 2; JANUS KINASE 3; PROTEIN KINASE TYK2;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME KINETICS; ENZYME PHOSPHORYLATION; ENZYME PURIFICATION; ENZYMOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION;

ANIMALS; CATALYSIS; HUMANS; JANUS KINASE 2; JANUS KINASE 3; MICE; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; TYK2 KINASE;

EID: 77952743472     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.04.141     Document Type: Article

References (26)

1. Wilks A.F. The JAK kinases: not just another kinase drug discovery target. Semin. Cell Dev. Biol. 19 (2008) 319-328
2. Ghoreschi K., Laurence A., and O'Shea J.J. Janus kinases in immune cell signaling. Immunol. Rev. 228 (2009) 273-287
3. Cacalano N.A., Mignone T.S., Bazan F., et al. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain. EMBO J. 18 (1999) 1549-1558
4. Thomas D.C., Lee W., and Berg L.J. T cells from Jak3-deficient mice have intact TCR signaling, but increased apoptosis. J. Immunol. 159 (1997) 4708-4719
5. Suzuki K., Nakajima H., and Saito Y. Kinase 3 (Jak3) is essential for common cytokine receptor γ chain (γc)-dependent signaling: comparative analysis of γc, Jak3, and γc and Jak3 double-deficient mice. Int. Immunol. 12 (2000) 123-132
6. Baxter E.J., Scott L.M., Campbell P.J., et al. Cancer genome project. Acquired mutation of the tyrosine kinase Jak2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
7. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 434 (2005) 1144-1148
8. Kralavics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352 (2005) 1779-1790
9. Minegishi Y. Human tyrosine kinase-2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25 (2006) 745-755
10. Schindler T., Bornmann W., Pellicena P., et al. J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289 (2000) 1938-1942
11. Nagar B., Hantschel O., and Young M.A. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112 (2003) 859-871
12. Zhou Y.J., Hanson E.P., Chen Y.Q., et al. Distinct tyrosine phosphorulation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proc. Natl. Acad. Sci 94 (1997) 13850-13855
13. Gauzzi M.C., Velazquez L., McKendry R., et al. Interferon-α-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. J. Biol. Chem. 271 (1996) 20494-20500
14. Liu K.D., Gaffen S.L., Goldsmith M.A., and Greene W.C. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation. Curr. Biol. 7 (1997) 817-826
15. Feng F., Witthuhn B.A., Matsuda T., et al. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol. Cell Biol. 17 (1997) 2497-2501
16. J.E. Chrencik, A. Patny, I.K. Leung, et al., Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with PAN inhibitors, J. Mol. Biol. (2010), in press.
17. Hall T., Emmons T.E., Chrencik J., et al. Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain. Protein Expr. Purif. 69 (2010) 54-63
18. R.J. Leatherbarrow, Erithacus Software Ltd., 2001. Grafit Version 5.
19. Copeland R.A. Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis (2000), Wiley-VCH, New York
20. Lucet I.S., Fantino E., Styles M., et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107 (2006) 176-183
21. Boggon T.J., Li Y., Manley P.W., and Eck M.J. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 106 (2005) 996-1002
22. Changelian P.S., Flanagan M.E., Ball D.J., et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302 (2003) 875-878
23. Thompson J.E., Cubbon R.M., Cummings R.T., et al. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg. Med. Chem. Lett. 12 (2002) 1219-1223
24. Changelian P.S., Moshinsky D., Kuhn C.F., Flanagan M.E., et al. The specificity of JAK3 kinase inhibitors. Blood 111 (2008) 2155-2157
25. Knight Z.A., and Shokat K.M. Features of selective kinase inhibitors. Chem. Biol. 12 (2005) 621-637
26. Frantz B., Klatt T., Pang M., et al. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 37 (1998) 13846-13853